Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - IMMUNOMEDICS INC | a17-1650_2ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 12, 2016
Immunomedics, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
|
000-12104 |
|
61-1009366 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
300 The American Road, Morris Plains, New Jersey |
|
07950 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(973) 605-8200
(Registrant’s telephone number,
including area code
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On January 9, 2017, the Company issued a press release titled “Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan.” The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 hereto and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
|
Description of Exhibit |
|
99.1 |
|
Press Release of Immunomedics, Inc., dated January 9, 2017, titled “Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan” |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
IMMUNOMEDICS, INC. | |
|
|
| |
|
|
By: |
/s/ Michael R. Garone |
|
|
Name: |
Michael R. Garone |
|
|
Title: |
Vice President, Finance and Chief Financial Officer |
|
|
|
|
|
Date: January 9, 2017 |
|
|